Medications for postmenopausal osteoporosis prevention.
D019386:Alendronate / Q000627:therapeutic use; D015519:Bone Density; D004965:Estrogen Antagonists / Q000627:therapeutic use; D015914:Estrogen Replacement Therapy; D004966:Estrogens, Conjugated (USP) / Q000627:therapeutic use; D012968:Etidronic Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D015663:Osteoporosis, Postmenopausal / Q000188:drug therapy* / Q000517:prevention & control*; D020849:Raloxifene Hydrochloride / Q000627:therapeutic use; D000068296:Risedronic Acid; D012307:Risk Factors; D020845:Selective Estrogen Receptor Modulators / Q000627:therapeutic use
D004965:Estrogen Antagonists; D004966:Estrogens, Conjugated (USP); D020845:Selective Estrogen Receptor Modulators; D020849:Raloxifene Hydrochloride; D000068296:Risedronic Acid; D012968:Etidronic Acid; D019386:Alendronate